255 related articles for article (PubMed ID: 18519749)
1. Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients.
Cattelani S; Defferrari R; Marsilio S; Bussolari R; Candini O; Corradini F; Ferrari-Amorotti G; Guerzoni C; Pecorari L; Menin C; Bertorelle R; Altavista P; McDowell HP; Boldrini R; Dominici C; Tonini GP; Raschellà G; Calabretta B
Clin Cancer Res; 2008 Jun; 14(11):3248-53. PubMed ID: 18519749
[TBL] [Abstract][Full Text] [Related]
2. Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma.
Rihani A; Van Maerken T; De Wilde B; Zeka F; Laureys G; Norga K; Tonini GP; Coco S; Versteeg R; Noguera R; Schulte JH; Eggert A; Stallings RL; Speleman F; Vandesompele J
Pediatr Blood Cancer; 2014 Oct; 61(10):1867-70. PubMed ID: 24391119
[TBL] [Abstract][Full Text] [Related]
3. MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma.
Perfumo C; Parodi S; Mazzocco K; Defferrari R; Inga A; Scarrà GB; Ghiorzo P; Haupt R; Tonini GP; Fronza G
Pediatr Blood Cancer; 2009 Oct; 53(4):576-83. PubMed ID: 19526525
[TBL] [Abstract][Full Text] [Related]
4. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
[TBL] [Abstract][Full Text] [Related]
5. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
6. Impact of MDM2 SNP309 genotype on progression and survival of stage 4 neuroblastoma.
Perfumo C; Parodi S; Mazzocco K; Defferrari R; Inga A; Haupt R; Fronza G; Tonini GP
Eur J Cancer; 2008 Nov; 44(17):2634-9. PubMed ID: 18835771
[TBL] [Abstract][Full Text] [Related]
7. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
Nan H; Qureshi AA; Hunter DJ; Han J
Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
[TBL] [Abstract][Full Text] [Related]
8. MDM2 SNP309 genotype is associated with ferritin and LDH serum levels in children with stage 4 neuroblastoma.
Parodi S; Perfumo C; Garaventa A; Inga A; Mazzocco K; Defferrari R; Tonini GP; Fronza G; Haupt R
Pediatr Blood Cancer; 2010 Aug; 55(2):267-72. PubMed ID: 20232446
[TBL] [Abstract][Full Text] [Related]
9. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.
Walsh CS; Miller CW; Karlan BY; Koeffler HP
Gynecol Oncol; 2007 Mar; 104(3):660-4. PubMed ID: 17123590
[TBL] [Abstract][Full Text] [Related]
10. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
[TBL] [Abstract][Full Text] [Related]
11. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
12. Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk.
Petenkaya A; Bozkurt B; Akilli-Ozturk O; Kaya HS; Gur-Dedeoglu B; Yulug IG
Anticancer Res; 2006; 26(6C):4975-7. PubMed ID: 17214373
[TBL] [Abstract][Full Text] [Related]
13. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis.
Ohmiya N; Taguchi A; Mabuchi N; Itoh A; Hirooka Y; Niwa Y; Goto H
J Clin Oncol; 2006 Sep; 24(27):4434-40. PubMed ID: 16983111
[TBL] [Abstract][Full Text] [Related]
14. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E
Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891
[TBL] [Abstract][Full Text] [Related]
15. The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme.
Khatri RG; Navaratne K; Weil RJ
J Neurosurg; 2008 Nov; 109(5):842-8. PubMed ID: 18976073
[TBL] [Abstract][Full Text] [Related]
16. MDM2 SNP309 associates with accelerated pancreatic adenocarcinoma formation.
Grochola LF; Müller TH; Bond GL; Taubert H; Udelnow A; Würl P
Pancreas; 2010 Jan; 39(1):76-80. PubMed ID: 19752772
[TBL] [Abstract][Full Text] [Related]
17. Impact of the Mdm2(SNP309-G) allele on a murine model of colorectal cancer.
Zhang X; Pageon L; Post SM
Oncogene; 2015 Aug; 34(33):4412-20. PubMed ID: 25435368
[TBL] [Abstract][Full Text] [Related]
18. A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells.
Hu W; Feng Z; Ma L; Wagner J; Rice JJ; Stolovitzky G; Levine AJ
Cancer Res; 2007 Mar; 67(6):2757-65. PubMed ID: 17363597
[TBL] [Abstract][Full Text] [Related]
19. Association of rheumatoid arthritis with Mdm2 SNP309 and genetic evidence for an allele-specific interaction between MDM2 and p53 P72R variants: a case control study.
Assmann G; Voswinkel J; Mueller M; Bittenbring J; Koenig J; Menzel A; Pfreundschuh M; Roemer K; Melchers I
Clin Exp Rheumatol; 2009; 27(4):615-9. PubMed ID: 19772793
[TBL] [Abstract][Full Text] [Related]
20. Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers.
Copson ER; White HE; Blaydes JP; Robinson DO; Johnson PW; Eccles DM
BMC Cancer; 2006 Mar; 6():80. PubMed ID: 16563154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
